查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1971377

植物性止血粉市场－全球产业规模、份额、趋势、机会、预测：按类型、应用、地区和竞争格局划分，2021-2031年

Plant-based Hemostat Powder Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (1g, 3g, 5g, Others), By Application (Surgical Wound Care, General Wound Care), By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球植物来源止血粉市场预计将从 2025 年的 2.0459 亿美元成长到 2031 年的 3.5812 亿美元，复合年增长率为 9.78%。

这些可吸收、生物相容性良好的手术辅助剂通常由氧化纤维素和马铃薯淀粉等多醣製成，旨在促进自然凝血过程，并控制小动脉、静脉和毛细血管的出血。推动这一领域发展的主要因素是复杂手术的日益频繁以及需要手术干预的慢性疾病在全球范围内日益加重。因此，高效的术中出血管理对于减少併发症至关重要。根据欧洲医疗技术协会（MedTech Europe）的数据，2024年欧洲将进行超过6,300万例手术，凸显了对能够维持手术效率和安全性的医疗技术的迫切需求。

市场概览
预测期 2027-2031
市场规模：2025年 2.0459亿美元
市场规模：2031年 3.5812亿美元
复合年增长率：2026-2031年 9.78%
成长最快的细分市场 外科性创伤护理
最大的市场 北美洲

然而，针对这些III类医疗设备的严格法规环境，特别是对疗效和安全性的要求，对市场成长构成了重大障碍。为满足复杂的合规标准（例如欧盟医疗设备法规 (EU MDR)），需要提供强有力的临床证据，这提高了准入门槛并延长了核准时间。这种监管负担可能会显着延迟新型植物来源止血产品的上市，增加製造商的研发成本，并最终限制这些创新技术应用于医疗产业。

市场驱动因素

全球外科手术和创伤事件的日益频繁是植物来源止血粉市场发展的主要驱动力。随着医疗机构面临应对急性创伤和减少择期手术的双重压力，对这些高吸收率和生物相容性止血剂的需求也日益增长。尤其是在大出血的创伤现场，这些止血粉至关重要，因为它们能够快速脱水并促进血液凝固，并避免了动物性产品固有的病毒感染风险。世界卫生组织（WHO）在2024年6月发布的报告进一步凸显了这项需求的迫切性：创伤每年导致全球440万人死亡，凸显了对有效止血解决方案的巨大需求。此外，择期手术数量的增加也加剧了这项需求。根据英国国家医疗服务体系（NHS）统计，截至2024年8月，非紧急治疗的候诊名单已达760万人，这意味着大量需要手术耗材的手术正在等待进行。

同时，随着微创手术和机器人手术的日益普及，人们越来越倾向于使用粉末状止血剂而非传统的布质止血剂。这些液体止血剂特别适用于腹腔镜手术环境，因为它们可以透过细小的套管针精准给药，并能有效处理难以触及的解剖部位的不规则出血。这种技术上的兼容性正随着机器人系统的普及而推动市场显着成长。例如，直觉外科公司在其2024年10月的财报中披露，全球达文西手术的数量年增约18%。这表明，依赖用途广泛且易于使用的辅助剂（例如植物来源止血粉）的机器人手术平台正被越来越多的医生所采用。

市场挑战

严格的安全性和有效性监管要求是植物来源止血粉市场发展的主要障碍。由于这些产品通常因其可吸收性和与血液循环系统的直接接触而被归类为III类医疗设备，因此必须接受严格的生物相容性审查。製造商必须遵守复杂的合规体系，提供全面的临床验证，这显着增加了研发成本并需要投入大量资源。这些财务和营运压力大幅提高了市场进入门槛，阻碍了中小企业进入市场，并抑制了行业创新步伐。

这些监管障碍的直接后果是产品上市时间明显延长。根据欧洲医疗技术协会（MedTech Europe）2024年的数据，根据医疗设备法规（MDR），高风险医疗设备获得认证平均需要约18个月，这主要是由于认证机构的处理能力有限。如此漫长的核准週期延缓了新型止血解决方案在医疗领域的应用，从而限制了製造商的产生收入能力以及及时响应紧急临床需求的能力。

市场趋势

内视镜喷雾输送系统的专业化进步显着推动了市场发展，使得在胃肠内视镜检查过程中能够以非侵入性方式应用植物来源粉末成为可能。製造商正在开发基于导管的工具，这些工具可透过标准内视镜，将多醣粉末直接输送到胃肠道不规则出血点，克服了机械夹在潮湿和复杂解剖结构中的局限性。这项创新使得息肉切除术和消化性溃疡的毛细血管出血能够快速控制，无需进行开放性手术手术或腹腔镜手术。为了反映该应用领域的成长，Olympus Corporation于2024年3月宣布，其植物来源止血喷雾技术已覆盖美国49个州，并已交付超过5000套试剂盒，这表明此类液体溶液在胃肠道领域得到了迅速的临床应用。

同时，随着医疗专业人员致力于在控制出血的同时降低手术部位感染（SSI）的发生率，将抗菌成分融入植物来源配方的做法也日益普遍。业内相关人员正透过在纤维素和淀粉衍生的粉末中添加生物相容性抗菌剂，开发具有双重功能的器械——既能促进凝血，又能抑制伤口部位的细菌生长。这一发展直接应对了医院获得性感染日益增长的经济和临床影响，并推动了对维持无菌安全标准的辅助产品的需求。世界卫生组织（WHO）强调了这些预防策略的紧迫性，并在2024年11月发布报告称，到2050年，有效的感染控制措施每年可预防多达82.1万人死亡。这强烈鼓励使用能够主动降低感染风险的止血剂。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：植物性止血粉的全球市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依规格（1克、3克、5克、其他）
    • 依应用领域（外科性创伤护理、一般创伤护理）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美植物性止血粉市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲植物性止血粉市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区植物性止血粉市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲植物性止血粉市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲植物性止血粉市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球植物性止血粉市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Ethicon Inc.
  • Baxter International Inc
  • Becton Dickinson & Co
  • Bioceres SA
  • Grena AS/Norway
  • PlantTec Medical GmbH
  • Starch Medical Inc
  • Theracion Biomedical
  • Singclean Medical
  • Hemostasis, LLC

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 19031

The Global Plant-based Hemostat Powder Market is projected to expand from USD 204.59 Million in 2025 to USD 358.12 Million by 2031, reflecting a compound annual growth rate of 9.78%. These absorbable, biocompatible surgical adjuncts, typically derived from polysaccharides like oxidized cellulose or potato starch, are engineered to expedite the natural coagulation process and manage arteriolar, venous, and capillary bleeding. A major catalyst for this growth is the increasing frequency of complex surgical operations and the growing global burden of chronic conditions that necessitate surgical intervention, thereby creating a critical need for efficient intraoperative hemorrhage control to reduce complications. Data from MedTech Europe indicates that in 2024, more than 63 million surgical procedures took place across Europe, underscoring the vital demand for medical technologies that uphold procedural efficiency and safety.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 204.59 MIllion
Market Size 2031USD 358.12 MIllion
CAGR 2026-20319.78%
Fastest Growing SegmentSurgical Wound Care
Largest MarketNorth America

However, market growth faces significant obstacles due to the strict regulatory environment governing these Class III medical devices, especially concerning efficacy and safety requirements. The necessity for robust clinical evidence to satisfy complex compliance standards, such as the European Union Medical Device Regulation, establishes high entry barriers and extends approval timeframes. This regulatory weight can substantially postpone the market launch of novel plant-based hemostatic products and escalate development expenses for manufacturers, ultimately restricting the pace at which these innovations become available to the healthcare industry.

Market Driver

The escalating global frequency of surgical procedures and trauma incidents serves as a fundamental driver for the plant-based hemostat powder market. As medical providers encounter increasing pressure to address acute injuries and clear backlogs of elective surgeries, the demand for these absorbable, biocompatible agents has intensified. These powders are particularly indispensable in high-volume trauma scenarios due to their ability to rapidly dehydrate blood and hasten clotting without the viral transmission risks inherent in animal-derived alternatives. Underscoring the magnitude of this need, the World Health Organization reported in June 2024 that injuries cause 4.4 million deaths globally each year, highlighting a vast requirement for effective bleeding control solutions. Furthermore, the volume of pending surgeries exacerbates this demand; according to NHS England, the waiting list for non-emergency treatments hit 7.6 million pathways by August 2024, indicating a substantial pipeline of operations requiring surgical consumables.

Simultaneously, the rising uptake of minimally invasive and robotic surgeries is fueling a preference for powder-based formulations over conventional textile hemostats. These flowable agents are distinctly appropriate for laparoscopic settings, as they can be accurately deployed through narrow trocars to address irregular bleeding on difficult-to-access anatomical surfaces. This technical compatibility is stimulating notable market expansion as robotic systems become more prevalent. For instance, Intuitive Surgical revealed in their October 2024 earnings report that global da Vinci procedures rose by approximately 18% year-over-year, illustrating the growing reach of robotic platforms that depend on versatile, easily applicable adjuncts such as plant-based hemostatic powders.

Market Challenge

Strict regulatory mandates concerning safety and efficacy represent a major hurdle impeding the progress of the plant-based hemostat powder market. Since these products are typically categorized as Class III medical devices due to their absorbable properties and direct contact with the bloodstream, they are subject to intense scrutiny to guarantee biocompatibility. Manufacturers are required to maneuver through intricate compliance systems that necessitate comprehensive clinical proof, a process that substantially drives up development costs and demands significant resource allocation. This financial and operational pressure establishes formidable barriers to entry, often deterring smaller enterprises from joining the market and stifling the rate of innovation within the industry.

The immediate result of these regulatory obstacles is a distinct delay in bringing products to market. Data from MedTech Europe in 2024 highlights that certifying high-risk medical devices under the Medical Device Regulation took an average of nearly 18 months, largely due to capacity limitations among notified bodies. Such extended approval periods stall the debut of new hemostatic solutions in the healthcare arena, thereby constraining manufacturers' capacity to generate income and address pressing clinical requirements in a timely manner.

Market Trends

The advancement of specialized endoscopic spray delivery systems is notably propelling the market forward by facilitating the non-invasive application of plant-based powders during gastrointestinal interventions. Manufacturers are developing catheter-based tools that pass through standard endoscopes to deposit polysaccharide powders directly onto irregular bleeding areas within the GI tract, resolving the shortcomings of mechanical clips in moist, complex anatomies. This innovation permits swift management of capillary bleeding following polypectomies or in peptic ulcers without requiring open or laparoscopic surgery. Confirming the growth of this application, Olympus Corporation announced in March 2024 that its plant-based hemostatic spray technology has been distributed across 49 U.S. states with over 5,000 kits shipped, demonstrating the swift clinical adoption of these flowable solutions in gastroenterology.

At the same time, the integration of antimicrobial qualities into plant-based formulations is becoming increasingly popular as healthcare providers aim to lower surgical site infections (SSIs) while managing hemorrhage. Industry participants are augmenting cellulose and starch-derived powders with biocompatible antimicrobial agents to produce dual-function devices that not only speed up clotting but also prevent bacterial growth at the wound site. This development directly addresses the rising economic and clinical impact of hospital-acquired infections, fueling the demand for adjuncts that uphold sterile safety standards. Emphasizing the urgency of such preventive strategies, the World Health Organization reported in November 2024 that effective infection control measures could prevent up to 821,000 deaths annually by 2050, providing a powerful incentive for the use of hemostats that actively mitigate infection risks.

Key Market Players

  • Ethicon Inc.
  • Baxter International Inc
  • Becton Dickinson & Co
  • Bioceres SA
  • Grena AS/Norway
  • PlantTec Medical GmbH
  • Starch Medical Inc
  • Theracion Biomedical
  • Singclean Medical
  • Hemostasis, LLC

Report Scope

In this report, the Global Plant-based Hemostat Powder Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Plant-based Hemostat Powder Market, By Type

  • 1g
  • 3g
  • 5g
  • Others

Plant-based Hemostat Powder Market, By Application

  • Surgical Wound Care
  • General Wound Care

Plant-based Hemostat Powder Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Plant-based Hemostat Powder Market.

Available Customizations:

Global Plant-based Hemostat Powder Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Plant-based Hemostat Powder Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (1g, 3g, 5g, Others)
    • 5.2.2. By Application (Surgical Wound Care, General Wound Care)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Plant-based Hemostat Powder Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Plant-based Hemostat Powder Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Plant-based Hemostat Powder Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Plant-based Hemostat Powder Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application

7. Europe Plant-based Hemostat Powder Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Plant-based Hemostat Powder Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
    • 7.3.2. France Plant-based Hemostat Powder Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Plant-based Hemostat Powder Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Plant-based Hemostat Powder Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Plant-based Hemostat Powder Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application

8. Asia Pacific Plant-based Hemostat Powder Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Plant-based Hemostat Powder Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
    • 8.3.2. India Plant-based Hemostat Powder Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Plant-based Hemostat Powder Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Plant-based Hemostat Powder Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Plant-based Hemostat Powder Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application

9. Middle East & Africa Plant-based Hemostat Powder Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Plant-based Hemostat Powder Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE Plant-based Hemostat Powder Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa Plant-based Hemostat Powder Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application

10. South America Plant-based Hemostat Powder Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Plant-based Hemostat Powder Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia Plant-based Hemostat Powder Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina Plant-based Hemostat Powder Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Plant-based Hemostat Powder Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Ethicon Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Baxter International Inc
  • 15.3. Becton Dickinson & Co
  • 15.4. Bioceres SA
  • 15.5. Grena AS/Norway
  • 15.6. PlantTec Medical GmbH
  • 15.7. Starch Medical Inc
  • 15.8. Theracion Biomedical
  • 15.9. Singclean Medical
  • 15.10. Hemostasis, LLC

16. Strategic Recommendations

17. About Us & Disclaimer